Calquence tablet formulation approved in the US across current indications


5 August 2022 - New formulation can be co-administered with gastric acid-reducing agents.

AstraZeneca’s new tablet formulation of Calquence (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukaemia, small lymphocytic lymphoma and for patients with relapsed or refractory mantle cell lymphoma, which is approved under accelerated approval based on overall response rate.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , US